


IP22: Walking a Tightrope: How to Balance Real-World Data Quality Versus Locality in Supporting Single-Arm HTA Submissions?

EU ISPOR 2022

Tuesday, 8 November 2022



Polling question 1

Which of the following quality elements do you think is most important for choosing an RWE external control in single-arm submissions?

(Please select one)



A. Prospective data collection

C. Data availability and completeness to allow adjusting for potential confounders

B. Population and outcomes comparability

D. Sample size

Polling question 2

Which of the following elements do you think the HTA bodies will trade-off for using local versus international RWE external control in single-arm submissions?

(Please select one)



A.

Representative of patients, care settings, pathways

C.

Currency (or timeliness)

B.

Data content and granularity

D.

Sample size and follow up

Polling question 3

What do you think would be the main driver increasing HTA acceptance to international RWE external control data? (please select one)

(Please select the most important)



A.

Greater availability and higher quality of RWE data

C.

Improved understanding of RWE methods

B.

Shifting clinical trial development landscape (innovative medicines, precision medicine, single-arm trials)

D.

Legislation drive for standardised RWE data collection

E.

International HTA Collaborations